• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Shlimak Anna

    3/20/26 5:11:07 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shlimak Anna

    (Last)(First)(Middle)
    4491 CONCESSION RD 12

    (Street)
    STAYNERL0M 1S0

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Cronos Group Inc. [ CRON ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    See Remarks
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/19/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    COMMON SHARES03/19/2026M28,429A$0(1)368,362D
    COMMON SHARES03/19/2026F9,767D$2.54358,595D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    RESTRICTED STOCK UNITS(1)03/19/2026M28,429 (2) (2)COMMON SHARES28,429$0386,893D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") represents a contingent right to receive one common share of Cronos Group Inc.
    2. On March 19, 2025, the Reporting Person was granted 85,297 RSUs, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.
    Remarks:
    Chief Financial Officer
    /s/ Aaron Werner, as attorney-in-fact for Anna Shlimak03/20/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $CRON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    More analyst ratings

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles

    TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabis company, is expanding its lineup of SOURZ by Spinach® Fully Blasted multipacks to meet consumer demand for edible products during the summer season. The lineup of SOURZ by Spinach® Fully Blasted multipacks with liquid diamond-infused gummies now includes the brand’s popular flavors featuring rare cannabinoid formulations, along with a new limited-time offer (LTO) flavor for the summer months. SOURZ by Spinach® Fully Blasted multipacks are the #1 edible multipack in Canada, capturing 31.7% share of all 10x10 pack sales in May 2026¹. The Spinach® brand continues to

    7/21/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026

    TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/16/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada

    TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company, announced today that it has appointed ATB Capital Markets Corp. ("ATB Cormark") to act as its broker in connection with share repurchases over the facilities of the TSX or other alternative Canadian trading systems, in place of Virtu Canada Corp., under its previously announced share repurchase program. About Cronos Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an ico

    6/30/26 5:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    SEC Filings

    View All

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Cronos Group Inc. (0001656472) (Filer)

    6/22/26 5:04:19 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Cronos Group Inc.

    10-Q - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:33:01 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:32:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity initiated coverage on Cronos Group

    Canaccord Genuity initiated coverage of Cronos Group with a rating of Buy

    1/27/26 9:29:20 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Broughton Darren Chester

    3 - Cronos Group Inc. (0001656472) (Issuer)

    6/30/26 4:06:24 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:49 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:02 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada

    TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company, announced today that it has appointed ATB Capital Markets Corp. ("ATB Cormark") to act as its broker in connection with share repurchases over the facilities of the TSX or other alternative Canadian trading systems, in place of Virtu Canada Corp., under its previously announced share repurchase program. About Cronos Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an ico

    6/30/26 5:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders

    TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the "Meeting"), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for th

    6/22/26 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026

    TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/16/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026

    TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    4/20/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    2/12/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    12/19/22 8:47:03 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care